1. Home
  2. SJT vs BWAY Comparison

SJT vs BWAY Comparison

Compare SJT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

HOLD

Current Price

$5.72

Market Cap

282.0M

Sector

Energy

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$16.95

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SJT
BWAY
Founded
1980
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.0M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SJT
BWAY
Price
$5.72
$16.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
198.2K
59.2K
Earning Date
11-13-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
$24,557.00
$49,094,000.00
Revenue This Year
N/A
$330.76
Revenue Next Year
N/A
$22.24
P/E Ratio
N/A
$54.90
Revenue Growth
N/A
27.08
52 Week Low
$3.66
$7.84
52 Week High
$7.22
$18.18

Technical Indicators

Market Signals
Indicator
SJT
BWAY
Relative Strength Index (RSI) 47.25 54.82
Support Level $5.82 $16.75
Resistance Level $6.20 $18.18
Average True Range (ATR) 0.24 0.74
MACD 0.01 0.10
Stochastic Oscillator 54.74 69.37

Price Performance

Historical Comparison
SJT
BWAY

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: